JP2019511483A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511483A5
JP2019511483A5 JP2018545910A JP2018545910A JP2019511483A5 JP 2019511483 A5 JP2019511483 A5 JP 2019511483A5 JP 2018545910 A JP2018545910 A JP 2018545910A JP 2018545910 A JP2018545910 A JP 2018545910A JP 2019511483 A5 JP2019511483 A5 JP 2019511483A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
cycloalkyl
pharmaceutical composition
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018545910A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511483A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/020451 external-priority patent/WO2017151922A1/en
Publication of JP2019511483A publication Critical patent/JP2019511483A/ja
Publication of JP2019511483A5 publication Critical patent/JP2019511483A5/ja
Pending legal-status Critical Current

Links

JP2018545910A 2016-03-02 2017-03-02 免疫療法のためのsting活性化ナノワクチン Pending JP2019511483A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302637P 2016-03-02 2016-03-02
US62/302,637 2016-03-02
PCT/US2017/020451 WO2017151922A1 (en) 2016-03-02 2017-03-02 Sting activating nanovaccine for immunotherapy

Publications (2)

Publication Number Publication Date
JP2019511483A JP2019511483A (ja) 2019-04-25
JP2019511483A5 true JP2019511483A5 (enExample) 2020-04-09

Family

ID=59743242

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018545910A Pending JP2019511483A (ja) 2016-03-02 2017-03-02 免疫療法のためのsting活性化ナノワクチン

Country Status (9)

Country Link
US (1) US11376324B2 (enExample)
EP (1) EP3423044A4 (enExample)
JP (1) JP2019511483A (enExample)
KR (1) KR20180114946A (enExample)
CN (1) CN109069440A (enExample)
AU (1) AU2017225769B2 (enExample)
CA (1) CA3016457A1 (enExample)
MX (1) MX2018010586A (enExample)
WO (1) WO2017151922A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280430B2 (en) 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
CA3029644A1 (en) 2016-07-06 2018-01-11 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
EP3675859A4 (en) 2017-08-31 2021-06-30 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
US11707531B2 (en) 2017-09-11 2023-07-25 F-star Therapeutics, Inc. Compounds, compositions, and methods for the treatment of disease
CN111556760A (zh) * 2017-11-06 2020-08-18 纪念斯隆-凯特林癌症中心 作为疫苗免疫佐剂的热灭活的牛痘病毒
CN111727054A (zh) * 2018-01-04 2020-09-29 中央研究院 用于增加疗效的可与细胞结合的免疫佐剂
JP7542257B2 (ja) * 2018-01-25 2024-08-30 エイシーエム バイオラブズ プライベート リミテッド 可溶化された封入抗原を含むポリマーソーム、ならびにその作製および使用方法
EP3743103A4 (en) * 2018-01-26 2021-03-17 The Regents of The University of California INTRANASAL ADMINISTRATION OF CYCLIC DI-NUCLEOTIDE ADJUVED VACCINE FOR TUBERCULOSIS
EP3802534B1 (en) 2018-05-25 2022-07-13 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020014127A1 (en) 2018-07-10 2020-01-16 Sperovie Biosciences, Inc. Compounds, compositions, and methods for the treatment of disease
US10875872B2 (en) 2018-07-31 2020-12-29 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020028565A1 (en) 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
CN109453364B (zh) * 2018-09-30 2021-10-15 郑州大学第一附属医院 一种双重响应性纳米颗粒及其在肿瘤抑制中的应用
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020146237A1 (en) 2019-01-07 2020-07-16 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020178769A1 (en) * 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
BR112021023940A2 (pt) * 2019-05-28 2022-02-15 Univ Texas Composições responsivas ao ph e usos das mesmas
KR20220024565A (ko) 2019-06-22 2022-03-03 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 생분해성 초-pH 민감성 중합체
BR112022008849A2 (pt) * 2019-11-07 2022-08-23 Samyang Holdings Corp Composição para induzir imunidade a um ingrediente ativo, e, método para preparar uma composição para induzir imunidade a um ingrediente ativo
AU2020387279B2 (en) * 2019-11-18 2026-04-09 Onconano Medicine, Inc. pH responsive compositions, formulations, and methods of imaging a tumor
GB201918963D0 (en) * 2019-12-20 2020-02-05 Provost Fellows Scholars And Other Members Of Board Of Trinity College Dublin Polymeric nanoparticles as vaccine adjuvants
CN111184738B (zh) * 2020-03-04 2021-05-28 北京大学 一种二嵌段共聚物或其药学上可接受的盐在制备抗病毒药物中的应用、药物组合物
CN113577255B (zh) * 2020-04-30 2023-09-08 中国科学院上海药物研究所 肿瘤纳米疫苗、其制备方法及用途
MX2023002797A (es) * 2020-09-08 2023-05-04 Univ Texas Composiciones activadoras de sting polivalente y usos de las mismas.
EP4240781A4 (en) * 2020-11-03 2026-02-18 Onconano Medicine Inc pH-sensitive therapeutic compositions
EP4066824A1 (en) * 2021-03-31 2022-10-05 Dompe' Farmaceutici S.P.A. Combination therapy for covid-19 vaccination
US20250127921A1 (en) * 2021-08-10 2025-04-24 Wisconsin Alumni Research Foundation Ph-responsive nano particle for delivery of ribonucleoproteins
WO2023142341A1 (zh) * 2022-01-26 2023-08-03 深圳湾实验室坪山生物医药研发转化中心 肿瘤免疫治疗
CN114456331A (zh) * 2022-02-16 2022-05-10 北京大学 能够与膜结合的聚合物及其制备方法和用途
WO2024226815A2 (en) * 2023-04-28 2024-10-31 University Of Washington B-cell epitopes of treponema pallidum antigens for use in a syphilis vaccine

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520019A (en) 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579945A (en) 1982-04-29 1986-04-01 Ribi Immunochem Research, Inc. Purification of trehalose dimycolates
US4505899A (en) 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4435386A (en) 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4505900A (en) 1982-05-26 1985-03-19 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5416070A (en) 1988-07-08 1995-05-16 Immunotherapeutics, Inc. Composition for macrophage activation
US4950645A (en) 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
IT1306129B1 (it) 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti Esteri della l-carnitina o di alcanoil l-carnitine utilizzabili comelipidi cationici per l'immissione intracellulare di composti
EP1326865B1 (en) 2000-10-12 2009-05-06 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
CN1370601A (zh) * 2001-02-22 2002-09-25 中国科学院成都有机化学研究所 单剂基因工程乙肝疫苗缓释微球的制备方法
US20050175625A1 (en) * 2002-07-12 2005-08-11 The Johns Hopkins University Mesothelin vaccines and model systems
US9200036B2 (en) * 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
ES2259914B1 (es) * 2005-03-14 2007-06-16 Advanced In Vitro Cell Technologies, S.L. Nanoparticulas de quitosano y polietilenglicol como sistema de administracion de moleculas biologicamente activas.
JP2008540558A (ja) * 2005-05-10 2008-11-20 エモリー・ユニバーシティ ミセルおよび粒子を用いた、活性物質の送達のための新規の戦略
EP2139513B1 (en) * 2007-03-28 2012-09-05 National Institute of Immunology Polymer particles based vaccine
WO2008148057A2 (en) * 2007-05-23 2008-12-04 Vical Incorporated Cationic lipids compositions and methods for enhancing immune responses to vaccines
US9532956B2 (en) * 2009-04-18 2017-01-03 Massachusetts Institute Of Technology PH sensitive biodegradable polymeric particles for drug delivery
WO2010138193A2 (en) * 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
WO2012039741A1 (en) * 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Novel block copolymer and micelle compositions and methods of use thereof
US20140308363A1 (en) * 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US9511152B2 (en) * 2012-04-05 2016-12-06 The Board Of Regents Of The University Of Texas System Multicolored pH-activatable fluorescence nanoplatform
SG11201502796RA (en) * 2012-12-13 2015-05-28 Aduro Biotech Inc Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
CN106573076A (zh) * 2014-06-06 2017-04-19 德克萨斯大学系统董事会 pH响应聚合物库及其纳米探针
KR102764250B1 (ko) * 2015-09-14 2025-02-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 지질양이온성 덴드리머 및 이의 용도
CN105214097A (zh) * 2015-10-30 2016-01-06 中国科学院福建物质结构研究所 一种口服纳米疫苗运载体的免疫实施与检测技术
US11096899B2 (en) * 2018-09-07 2021-08-24 Wisconsin Alumni Research Foundation Bacterial membrane nanoparticles as an immunotherapy system for cancer treatment

Similar Documents

Publication Publication Date Title
JP2020508310A5 (enExample)
Huang et al. Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer
US11376324B2 (en) Sting activating nanovaccine for immunotherapy
HRP20200383T1 (hr) Ciljana vezna sredstva protiv b7-h1
JP2020532532A5 (enExample)
JP2019519503A5 (enExample)
ES2522042T3 (es) Composición de vacuna que comprende un ARN modificado con caperuza 5'
JP2021104038A5 (enExample)
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
JP2019088286A5 (enExample)
JP2017186337A5 (enExample)
JP2017538682A5 (enExample)
JP2017536344A5 (enExample)
JP2008528671A5 (enExample)
JP2015536954A5 (enExample)
JP2012162567A5 (enExample)
JP2020506884A5 (enExample)
CN108892700B (zh) 一类新型抗肿瘤化合物及其在制备抗肿瘤药物中的应用
JP6293882B2 (ja) 遺伝的に安定な腫瘍溶解性rnaウイルス、その製造方法およびその使用
JP2011500841A5 (enExample)
JP2019172707A (ja) スクアレンを含む両親媒性ポリアミノ酸高分子に基づくワクチンの免疫補助剤組成物
JP2009527463A5 (enExample)
RU2379055C1 (ru) Способ лечения онкологических заболеваний
JP2020506886A5 (enExample)
JP7034521B1 (ja) がんワクチン及びがんワクチンの製造方法